Clinical Trial Detail

NCT ID NCT02450591
Title Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Memorial Sloan Kettering Cancer Center
Indications

lung adenocarcinoma

Therapies

Erlotinib

Age Groups: adult

Additional content available in CKB BOOST